Results 241 to 250 of about 1,921,670 (307)

Building a precision therapeutics program at a tertiary care children's hospital

Pediatric Investigation, EarlyView.
Luke Hamilton, Heidi Trinkman, Diana Carrasco, Kaitlin Smith, Kelly Vallance, Alejandra Dominguez, Danielle Miller, Megan Gibbs, Anish Ray   +8 more
wiley   +1 more source

Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
We report our single‐center experience of transplant outcomes with a busulfan, fludarabine and melphalan‐based conditioning regimen for children < 18 years of age. The regimen was shown to be well tolerated and effective for heavily pretreated children with high‐risk myeloid malignancies prior to allogeneic hematopoietic stem cell transplant.
Mayank Dhamija, Fiona Kerr, Hazel Gough, Johnathan Soggee, Laurence C. Cheung, Rishi S. Kotecha, Shanti Ramachandran   +6 more
wiley   +1 more source

[Retracted] SHIP1 is targeted by miR‑155 in acute myeloid leukemia. [PDF]

Oncol Rep
Xue H, Hua LM, Guo M, Luo JM.
europepmc   +1 more source

Basophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology and Application of the Basophil Activation Test

Allergy, EarlyView.
ABSTRACT Basophils, the least abundant leukocytes, are increasingly recognised as potent immunomodulators. Upon activation, they rapidly release preformed granule‐associated mediators including histamine and lipid mediators such as LTC4, while cytokine production occurs over a longer timescale, contributing to downstream immune responses.
Jitesh Chauhan, Sofia Vlasova, Alicia Chenoweth, Debra H. Josephs, Heather J. Bax, Sophia N. Karagiannis   +5 more
wiley   +1 more source

Host Fitness: A Missing Dimension of Precision Medicine in Older Acute Myeloid Leukemia. [PDF]

Hematol Oncol
Morabito F, Bruzzese A, Martino EA, Amodio N, Vigna E, Gentile M.   +5 more
europepmc   +1 more source

BRD9 inhibition as potential treatment option for testicular germ cell tumors

Andrology, EarlyView.
Abstract Background Testicular germ cell tumors (TGCT) are the predominant tumor in younger males. Usually, 5‐year survival rates are quite high, but 15–20% of patients with metastatic non‐seminomas are resistant to standard cisplatin‐based therapy.
Aylin Hansen, Christine Sanders, Florian Fronhoffs, Kai Funke, Glen Kristiansen, Hubert Schorle   +5 more
wiley   +1 more source

Acute myeloid leukemia with unusual mature lymphoid-like morphology in a subset of blasts. [PDF]

J Hematop
Vossen C, E Jordan C.
europepmc   +1 more source

Hemophagocytosis in acute myeloid leukemia

Hematology, Transfusion and Cell Therapy
Claudia Morales-Olvera, Fernando Pérez-Jacobo   +1 more
openaire   +3 more sources

A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells. [PDF]

Cancer Res
Kim BR, Kim H, Choi H, Kwag D, Kim YJ, Son H, Park S, Park J, Kim H, Choi W, Lee S, Kim HJ, Kang H, Jo H, Cho BS.   +14 more
europepmc   +1 more source